Sleep Apnea, Obstructive

The immediate cause is upper airway obstruction during sleep. The supplied grounding also associates the disorder with obesity, acromegaly, myxedema, micrognathia, myotonic dystrophy, adenotonsillar hypertrophy, and neuromuscular diseases. No additional etiologic causes are supported in the grounding.

Recurrent airway collapse during sleep produces repeated apneas and partial arousals. These events cause intermittent hypoxia, oxygen desaturation, and hypercapnia, which are linked in the literature to inflammation and neuron injury, particularly in the hippocampus and cortex. The disorder can also contribute to cardiovascular effects including arrhythmias and increased systemic and pulmonary arterial pressures.

Supported risk factors or associated conditions include obesity, acromegaly, myxedema, micrognathia, myotonic dystrophy, adenotonsillar hypertrophy, and neuromuscular diseases. The grounding also notes associations with hypertension and diabetes mellitus in the context of comorbidity and outcomes literature, but does not establish them as primary causal risk factors. No other risk factors are supported.

The grounding supports continuous positive airway pressure as a standard treatment modality, along with surgery in selected cases. It also mentions drug therapy in the literature and identifies glucagon-like peptide-1 receptor agonists as a studied therapeutic class, mainly in the context of obesity and diabetes-related treatment effects on obstructive sleep apnea. No specific regimen or dosing is supported.